Prof. Carmen Criscitiello is an associate professor at the
University of Milan and a scientist and senior physician appointed with High
Specialty in Immunotherapy at the Division of Early Drug Development at the
European Institute of Oncology in Milan, Italy. She is a clinician and
researcher committed to early drug development for patients with solid tumors,
with a special interest in breast cancer. She has been a member of the ESMO
Breast Cancer Faculty since 2017, Deputy Chair of the ESMO Leadership
Generation Task Force since 2020, a Member of the ESMO Press & Media
Affairs Committee since 2018, and an AIOM Breast Cancer Guidelines Panel Member
since 2018. She serves as an Associate Editor of the Frontiers in Oncology and
ESMO Open—Cancer Horizons. She is the global principal investigator of the
international and multicentric ALPHABET study.
Prof. Carmen Criscitiello is an associate professor at the
University of Milan and a scientist and senior physician appointed with High
Specialty in Immunotherapy at the Division of Early Drug Development at the
European Institute of Oncology in Milan, Italy. She is a clinician and
researcher committed to early drug development for patients with solid tumors,
with a special interest in breast cancer. She has been a member of the ESMO
Breast Cancer Faculty since 2017, Deputy Chair of the ESMO Leadership
Generation Task Force since 2020, a Member of the ESMO Press & Media
Affairs Committee since 2018, and an AIOM Breast Cancer Guidelines Panel Member
since 2018. She serves as an Associate Editor of the Frontiers in Oncology and
ESMO Open—Cancer Horizons. She is the global principal investigator of the
international and multicentric ALPHABET study.